• Something wrong with this record ?

Study of aberrant modifications in peptides as a test bench to investigate the immunological response to non-enzymatic glycation

F. Nuti, A. Gallo, F. Real-Fernandez, C. Rentier, G. Rossi, F. Piarulli, P. Traldi, S. Carganico, P. Rovero, A. Lapolla, A. M. Papini

. 2019 ; 65 (4) : 195-202.

Language English Country Czech Republic

Document type Journal Article

A side effect of diabetes is formation of glycated proteins and, from them, production of advanced early glycation end products that could determine aberrant immune responses at the systemic level. We investigated a relevant aberrant post-translational modification (PTM) in diabetes based on synthetic peptides modified on the lysine side chain residues with 1-deoxyfructopyranosyl moiety as a possible modification related to glycation. The PTM peptides were used as molecular probes for detection of possible specific autoantibodies developed by diabetic patients. The PDC-E2(167-186) sequence from the pyruvate dehydrogenase complex was selected and tested as a candidate peptide for antibody detection. The structure-based designed type I' β-turn CSF114 peptide was also used as a synthetic scaffold. Twenty-seven consecutive type 1 diabetic patients and 29 healthy controls were recruited for the study. In principle, the 'chemical reverse approach', based on the use of patient sera to screen the synthetic modified peptides, leads to the identification of specific probes able to characterize highly specific autoantibodies as disease biomarkers of autoimmune disorders. Quite surprisingly, both peptides modified with the (1-deoxyfructosyl)-lysine did not lead to significant results. Both IgG and IgM differences between the two populations were not significant. These data can be rationalized considering that i) IgGs in diabetic subjects exhibit a high degree of glycation, leading to decreased functionality; ii) IgGs in diabetic subjects exhibit a privileged response vs proteins containing advanced glycation products (e.g., methylglyoxal, glyoxal, glucosone, hydroimidazolone, dihydroxyimidazolidine) and only a minor one with respect to (1-deoxyfructosyl)-lysine.

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc20010291
003      
CZ-PrNML
005      
20200721125336.0
007      
ta
008      
200707s2019 xr ad f 000 0|eng||
009      
AR
035    __
$a (PubMed)31903893
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Nuti, F. $u Laboratory of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy
245    10
$a Study of aberrant modifications in peptides as a test bench to investigate the immunological response to non-enzymatic glycation / $c F. Nuti, A. Gallo, F. Real-Fernandez, C. Rentier, G. Rossi, F. Piarulli, P. Traldi, S. Carganico, P. Rovero, A. Lapolla, A. M. Papini
504    __
$a Literatura
520    9_
$a A side effect of diabetes is formation of glycated proteins and, from them, production of advanced early glycation end products that could determine aberrant immune responses at the systemic level. We investigated a relevant aberrant post-translational modification (PTM) in diabetes based on synthetic peptides modified on the lysine side chain residues with 1-deoxyfructopyranosyl moiety as a possible modification related to glycation. The PTM peptides were used as molecular probes for detection of possible specific autoantibodies developed by diabetic patients. The PDC-E2(167-186) sequence from the pyruvate dehydrogenase complex was selected and tested as a candidate peptide for antibody detection. The structure-based designed type I' β-turn CSF114 peptide was also used as a synthetic scaffold. Twenty-seven consecutive type 1 diabetic patients and 29 healthy controls were recruited for the study. In principle, the 'chemical reverse approach', based on the use of patient sera to screen the synthetic modified peptides, leads to the identification of specific probes able to characterize highly specific autoantibodies as disease biomarkers of autoimmune disorders. Quite surprisingly, both peptides modified with the (1-deoxyfructosyl)-lysine did not lead to significant results. Both IgG and IgM differences between the two populations were not significant. These data can be rationalized considering that i) IgGs in diabetic subjects exhibit a high degree of glycation, leading to decreased functionality; ii) IgGs in diabetic subjects exhibit a privileged response vs proteins containing advanced glycation products (e.g., methylglyoxal, glyoxal, glucosone, hydroimidazolone, dihydroxyimidazolidine) and only a minor one with respect to (1-deoxyfructosyl)-lysine.
650    _2
$a diabetes mellitus 1. typu $x metabolismus $7 D003922
650    _2
$a produkty pokročilé glykace $x metabolismus $7 D017127
650    _2
$a glykosylace $7 D006031
650    _2
$a glyoxal $x metabolismus $7 D006037
650    _2
$a lidé $7 D006801
650    _2
$a imidazoly $x metabolismus $7 D007093
650    _2
$a imunoanalýza $7 D007118
650    _2
$a ketosy $x metabolismus $7 D007661
650    _2
$a lysin $x chemie $x metabolismus $7 D008239
650    _2
$a peptidy $x chemie $x metabolismus $7 D010455
650    _2
$a posttranslační úpravy proteinů $7 D011499
650    _2
$a pyruvaldehyd $x metabolismus $7 D011765
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gallo, A. $u Diabetology and Dietetics, Department of Medicine (DIMED), University of Padova, Padova, Italy
700    1_
$a Real-Fernandez, F. $u Laboratory of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy
700    1_
$a Rentier, C. $u Laboratory of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy; PeptLab@UCP Platform and Laboratory of Chemical Biology EA4505, University Paris-Seine, Cergy-Pontoise CEDEX, France
700    1_
$a Rossi, G. $u Laboratory of Peptide and Protein Chemistry and Biology, Department of NeuroFarBa, University of Florence, Sesto Fiorentino, Italy; Pharma Quality Europe PQE SrL, Località Prulli, Firenze, Italy
700    1_
$a Piarulli, F. $u Diabetology and Dietetics, Department of Medicine (DIMED), University of Padova, Padova, Italy
700    1_
$a Traldi, P. $u Istituto di Ricerca Pediatrica, Città della Speranza, Padova, Italy
700    1_
$a Carganico, S. $u Laboratory of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy. Pharma Quality Europe PQE SrL, Località Prulli, Firenze, Italy
700    1_
$a Rovero, P. $u Laboratory of Peptide and Protein Chemistry and Biology, Department of NeuroFarBa, University of Florence, Sesto Fiorentino, Italy
700    1_
$a Lapolla, A. $u Diabetology and Dietetics, Department of Medicine (DIMED), University of Padova, Padova, Italy
700    1_
$a Papini, A. M. $u Laboratory of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy; PeptLab@UCP Platform and Laboratory of Chemical Biology EA4505, University Paris-Seine, Cergy-Pontoise CEDEX, France
773    0_
$w MED00011004 $t Folia biologica $x 0015-5500 $g Roč. 65, č. 4 (2019), s. 195-202
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31903893 $y Pubmed
856    41
$u https://fb.cuni.cz/file/5905/fb2019a0020.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 970 $c 89 $y p $z 0
990    __
$a 20200707 $b ABA008
991    __
$a 20200710110840 $b ABA008
999    __
$a ok $b bmc $g 1546286 $s 1100383
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 65 $c 4 $d 195-202 $i 0015-5500 $m Folia biologica (Praha) $n Folia biol. (Praha) $x MED00011004
LZP    __
$b NLK118 $a Pubmed-20200707

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...